EMEA approves Bydureon for type 2 diabetes.
European Medicines Evaluation Agency (EMEA) has approved hypoglycemic preparation Bydureon (Exenatide ) — the modified version of Baeta— for type 2 diabetes at adult patients.
Antidiabetic preparation Bydureon was in common developed by pharmaceutical companies Eli Lilly&Co., Amylin Pharmaceuticals Inc. and Alkermes Inc. The preparation in the form of injections stimulates secretion of insulin and is intended for application once a week.
Bydureon is the modified version of a preparation of Baeta which needs to be accepted twice a day. Observable side effect includes a moderate nausea, vomiting, a diarrhea, constipations, dysorexia and giddiness.
In October, 2010 FDA has refused to pass the positive decision on Bydureon, having demanded from the companies of the additional data about influence of the enlarged doses on cardiovascular system of patients.
Comments
(0)